We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 2,395

Health Alert (Australia) 20 February 2017
  • DLA Piper LLP
  • Australia
  • February 21 2017

In October 2016, Apotex brought proceedings against the Pfizer Group challenging the validity of a patent


When can a patent be infringed? The Federal Court provides some answers for the pharmaceutical industry
  • Griffith Hack
  • Australia
  • February 21 2017

Does an offer to supply a product before a patent expires infringe that patent? Yes. Does applying to list a drug on the Pharmaceutical Benefits


EPO delivers antidote for poisonous priority
  • FB Rice
  • Australia, European Union
  • February 17 2017

The Enlarged Board of Appeal of the EPO has taken the opportunity afforded by the referral of T0555713 (as discussed in our previous post) to


Federal Court of Australia confirms that offers made during patent term to supply after patent expiry constitute infringement
  • Shelston IP Lawyers Pty Ltd
  • Australia
  • February 17 2017

This week the Federal Court of Australia (Nicholas J) delivered a significant judgment in Apotex Pty Ltd v Warner-Lambert Company LLC (No 3) 2017


Australia Update: When is applying for listing on the Pharmaceutical Benefits Scheme not an infringement?
  • Spruson & Ferguson
  • Australia
  • February 16 2017

Apotex Pty Ltd v Warner-Lambert Company LLC (No 3) 2017 FCA 94 (15 February 2017


Licences are out and automatic rights are in: a new way to allow exploitation following temporary patent ceasing is proposed
  • FPA Patent Attorneys
  • Australia
  • February 15 2017

Automatic rights to exploit inventions are proposed to replace third party licences to exploit inventions. This proposal follows only months after an


The patent battle for the CRISPRCas9 gene editing technology: What patent applicants need to know
  • Griffith Hack
  • Australia, USA
  • February 14 2017

On 15 February 2017, the Patent Trial and Appeal Board (PTAB) handed down their one line decision on the CRISPR interference


Federal court aids in construction of provisions for third party statutory licences following temporary ceasing of a patent but declines to comment on Patent Office decision procedure
  • FPA Patent Attorneys
  • Australia
  • February 14 2017

The ground-breaking series of decisions, relating to AU 623144 (AU '144), which protected the antidepressant escitalopram, has generated another


To concede or not concede (infringement): that is the question! An instance of a third party licence being requested during temporary ceasing of a patent
  • FPA Patent Attorneys
  • Australia
  • February 14 2017

Under Australian law, if a patent application ceases and the patent is subsequently reinstated by the owner by use of our extension of time


Dentons' pick of global regulatory trends to watch in 2017
  • Dentons
  • Australia, Canada, China, European Union, Germany, Mexico, OECD, United Kingdom, USA
  • February 9 2017

Dentons’ team of regulatory lawyers from key jurisdictions around the world weigh in on regulatory trends to watch in 2017 in the US, Europe, the UK